Yarrow Bioscience Stock (NASDAQ:YARW)

Revenue Financials Chart

Previous Close

$20.00

52W Range

$16.04 - $46.95

50D Avg

$29.93

200D Avg

$31.19

Market Cap

$170.36M

Avg Vol (3M)

$92.05K

Beta

2.08

Div Yield

$20.10 (109.78%)

YARW Company Profile

Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

10

IPO Date

Jul 28, 2026

Website

YARW Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 25	Dec 24	Dec 22
Reportable Segment	$570.00K	$501.00K	-
Royalty	-	-	$477.00K

Fiscal year ends in Dec 25 | Currency in USD

YARW Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	$570.00K	$501.00K	$424.00K
Operating Income	$-29.75M	$-43.64M	$-29.26M
Net Income	$-26.48M	$-39.83M	$-28.45M
EBITDA	$-26.73M	$-39.80M	$-27.87M
Basic EPS	$-30.96	$-46.77	$-138.48
Diluted EPS	$-30.96	$-46.77	$-138.48

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q3 21Nov 10, 21 | 8:30 AM

Q2 21Aug 12, 21 | 8:30 AM

Q1 21May 06, 21 | 8:30 AM

Peer Comparison

Ticker	Company
XTLB	XTL Biopharmaceuticals Ltd.
TCRT	Alaunos Therapeutics, Inc.
KALA	KALA BIO, Inc.
SNGX	Soligenix, Inc.
KTTA	Pasithea Therapeutics Corp.
ENSC	Ensysce Biosciences, Inc.
QNRX	Quoin Pharmaceuticals, Ltd.
BCLI	Brainstorm Cell Therapeutics Inc.